Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dermisonics, Inc. (DMSI)
Irvine, CA, US
Dermisonics, Inc. develops and produces ultrasonic technologies and equipment for the transdermal administration of medications. A core focus for the company is the creation, evaluation, and market launch of its unique active transdermal patch, known as the U-Strip. This innovative patch is designed to facilitate the needle-free entry of large molecular weight drugs, like Insulin, directly into the circulatory system. The firm was originally incorporated as Second Stage Ventures, Inc. before adopting its current name, Dermisonics, Inc., in October 2004. Founded in 2000, the company maintains its principal offices in Irvine, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -70.00% | -70.00% | -99.00% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%—
-
EPS growth Medical - Specialties: +10.1%+29.4% ★ Q2'07: +66.7% (vs Q2'06)
-
FCF margin FCF growth · Medical - Specialties: +51.3%—
-
EBIT margin Medical - Specialties: +12.6%—
-
ROIC Medical - Specialties: +6.6%-24.1%
-
Share dilution Medical - Specialties: 0.0%+9.7% Q2'07: +31.5% (vs Q2'06)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.70× Q2'07: -1.60× (vs Q2'06)
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2006-03-27 | ATKINS GRANT R | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bruce H. Haglund | Executive Chairman, Acting Principal Executive,Financial & Accounting Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DMSI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
